February 20, 2017 / 6:21 AM / 5 months ago

BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million

1 Min Read

Feb 20 (Reuters) - Basilea Pharmaceutica AG:

* In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study

* Product sales of 7.1 million Swiss francs ($7.08 million) in europe and 7.3 million francs royalties received on 2016 Cresemba US sales

* 289 million francs cash and financial investments at 2016 year-end

* FY net loss 51.3 million francs versus 61.6 million francs year ago

* Sales for 2016 full year of 7.1 million francs in Europe Source text for Eikon: Further company coverage: ($1 = 1.0034 Swiss francs) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below